Chun 2014.
Methods | RCT Open‐label Loss to follow‐up reported: yes |
|
Participants | Persistent AF (mean duration: NS, in 38% of participants it was > 1 year). n = 100 Men: 81% Age (mean): 59 (SD 10) years Structural heart disease: NS. Mean LAD: 44 mm. Mean LVEF: 58% |
|
Interventions | Dronedarone 800 mg/day vs propafenone 450 mg/day Method of AF cardioversion: electrical Warfarin (or direct oral anticoagulants) discretionary, but 94% of participants were taking anticoagulants. |
|
Outcomes | At 6 months: AF recurrence |
|
Notes | We tried to contact authors of this study to request additional details on methods employed and outcomes analysed. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Described as randomised but procedure was not described. |
Allocation concealment (selection bias) | Unclear risk | Procedure to conceal allocations not described. |
Blinding (performance bias and detection bias) All outcomes | High risk | Open‐label study. |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Few withdrawals happened, balanced and well described. |
Selective reporting (reporting bias) | High risk | The only prespecified outcome was AF recurrence, and it was adequately reported. However, other important clinical outcomes, such as adverse events and deaths, would be expected in this type of study. |
Other bias | Low risk | No other bias apparent. |